Diabetes, Heart and Cardiovascular Diseases News Chronicle.  Diabetes, Cardiovascular and Heart Diseases
 Article 262
    Published on October 25, 2017

 

A Better HbA1c And No Hypoglycemia With Dapagliflozin (Forxiga) In Patients Of Type 1 Diabetes

Ads

Even though the blood sugar levels are under control in patients of type 1 diabetes (T1D), they may experience "glycemic excursions", (blood sugar levels changing from high levels to low levels) with insulin.


Dapagliflozin (Forxiga, SGLT2) can provide a better HbA1c control in patients of type 1 diabetes without hypoglycemia.

A study shows a marked reduction in the blood sugar levels without the episodes of low blood sugar (glucose) levels (hypoglycemia) in most of the patients of type 1 diabetes (T1D) with dapagliflozin. Currently, dapagliflozin was being used for the treatment of type 2 diabetes (T2D).



Ads Raspberry ketone max with a blend of green tea, chromium, caffeine and l theanine supplements to losing weight
See More Ads For "Body Weight Loss"

Researchers have conducted a 24 week study (in 17 countries including the United States) named as the "Dapagliflozin in Patients with Inadequately Controlled Type 1 Diabetes Study" (DEPICT-1), to find out the drug efficacy and safety as an adjunct treatment for insulin in patients of type 1 diabetes (T1D) with inadequately controlled blood glucose levels. The total number of participants in the first Phase 3 trial was 833, aged between 18 and 75 years.

The study shows that about 50 percent of the patients of type 1 diabetes (T1D) have successfully lowered their A1C levels by more than 0.5 percent without hypoglycemia (low blood sugar levels).


Ads A powerful treatment to take full control over your type 2 diabetes
See More Ads For "Reversal Of Diabetes"

The authors say that the dapagliflozin is eligible for approval by the United States FDA as an antidiabetic agent for patients of type 1 diabetes (T1D) as the drug can lower HbA1c levels by about 0.5 percent. But they say that the drug needs further study to confirm the current study.


This study was funded by Bristol-Myers Squibb and AstraZeneca, the development partners of dapagliflozin. Manufacturers may likely to apply for the United States FDA approval after the 56-week DEPICT-1 study and DEPICT-2 study (a parallel study of dapagliflozin).

The senior author of the study was Professor Paresh Dandona, MD, Ph.D., chief of Endocrinology, Diabetes and Metabolism, Jacobs School of Medicine and Biomedical Sciences, the University at Buffalo, United States.



Ads The simple steps to burn off belly fat in 14 days
See More Ads For "Lowering Body Fat"



        Twitter
If you like this article, please share it with a friend! Article address is (copy and paste the code below) :

Articles similar to this topic


Ads A simple method to eliminate or reverse diabetes
See More Ads For "Reversal Of Diabetes"

1. Trials Of GLP-1 (exenatide extended-release) And Farxiga (dapagliflozin)
2. Chronic Kidney Disease, Heart Disease & Diabetes Prevention Drugs From Forxiga Drug Maker AstraZeneca
3. Ghrelin Hormone Could Expand Diabetes Treatments And Hypoglycemia
4. Eating cocoa, chocolate reduces blood sugar or glucose levels, obesity and increases insulin secretion
5. Coronary artery bypass surgery (CABG) is effective in treating artherosclerotic coronary arteries among type 1 diabetes patients
6. Higher risk of the development type 1 diabetes (T1D) in early term or early birth babies
7. Trials Of Forxiga (Dapagliflozin), Victoza (Liraglutide) And Insulin Approach (Triple Therapy)

Ads Lose 13 pounds of fat safely every month
See More Ads For "Lowering Body Fat"

8. Toujeo Lowers Hypoglycemia Among Insulin Dependent Type 2 Diabetes Patients
9. MonoPepT1De trial shows a slowdown in the development of type 1 diabetes with a retrained immune system
10. A cure for Type 1 Diabetes (T1D) With Gene Transfer Technique

Ads An easy method to reverse high blood sugar levels
See More Ads For "Reversal Of Diabetes"

 

 

 

The Risk Of Type 1.5 Diabetes Or Latent Autoimmune Diabetes In Adults (LADA) With High Salt (Or Sodium) Consumption

Ads

A study at the Institute of Environmental Medicine (IMM), Karolinska Institutet, Sweden shows twice likely risk of diabetes, apart from the risk of high blood pressure (hypertension. BP) among people who consume more salt (as 40 percent of salt is sodium). The researchers say that the salt directly affects the insulin resistance.



The risk of type 1.5 diabetes or latent autoimmune diabetes in adults (LADA) with high salt (or sodium) diet.

The study shows 43 percent increased risk of type 2 diabetes (T2D) even with 2.5 grams of extra salt consumption (equal to one gram of sodium) per day. The study also shows 72 percent increased risk of type 2 diabetes (T2D) in individuals who consume more than 7.3 grams of salt per day when compared with individuals who consume less than six grams of salt per day.


Ads A science-based plan to melt away stubborn body fat in just 14 days
See More Ads For "Lowering Body Fat"

The authors says that the people with human leukocyte antigen (HLA) and consuming high amounts of salt (more than 3.15 grams of salt per day) are at four times higher risk of type 1.5 diabetes or latent autoimmune diabetes in adults (LADA) compared with people consuming low amounts of salt (less than 2.4 grams of salt per day).

The lead author of the study was Bahareh Rasouli, the Institute of Environmental Medicine (IMM). The study was presented at the annual meeting of the European Association for the Study of Diabetes (EASD) 2017, Lisbon, Portugal and published on September 14, 2017, in the Diabetologia. Title of the article was "Sodium (salt) intake is associated with a risk of developing type 2 diabetes."



Ads Evidence shows 297% increased fat loss without painful diets or increasing exercise
See More Ads For "Lowering Body Fat"



        Twitter
Post a message on social media and mail to your friend. Article address is (copy and paste the code below) :

Articles similar to this topic


Ads A weird metabolic trick to see a flat and firm belly in only 19 days
See More Ads For "Body Weight Loss"

1. Too much salt consumption may double heart failure, stroke and coronary heart disease (CHD)
2. Salty Skin In People With Kidney Disease Could Be A Sign Of a Heart Problem
3. Insufficient sleep hours increases the risk for type 2 diabetes, insulin resistance and body fat in children
4. Neovacs Vaccine To Treat Type 1 Diabetes (T1D)
5. ViaCyte conducts embryonic stem cell implant trials in high-risk type 1 diabetes patients
6. High Salt Diet Putting Teens At Risk Of Heart Disease Later In Life
7. Increase In Diabetes And Insulin Resistance With Climate Change

Ads A science-based plan to get rid of stubborn fat in 5 weeks
See More Ads For "Lowering Body Fat"

8. About type 1 disease (T1D) And type 2 Diabetes (T2D)
9. Enhanced risk for celiac disease in type 1 diabetes in children
10. Limit Consumption Of Salt, Sugar And Saturated Fat To Keep Good Heart Health

Ads A simple 21-minutes a day weight loss system to burn fat (21 pounds)
See More Ads For "Lowering Body Fat"

 

Type 1.5 diabetes: Type 1.5 diabetes or latent autoimmune diabetes in adults (LADA) is a type 1 diabetes (T1D) which appears during adulthood. The onset of LADA in adulthood is slower when compared to the onset of type 1 diabetes (T1D) in childhood. This occurs due to the destruction or damage to the insulin-producing beta cells in the pancreas.


Ads A simple way to get a flat stomach and a lean body
See More Ads For "Body Weight Loss"

 

 

Sitemaps

Sitemap 1   Sitemap 2   Sitemap 3   Sitemap 4


The Diabetes News Chronicle does not provide medical advice, diagnosis or treatment. Information in Diabetes News Chronicle is to support and not to replace medical advice given by the surgeon or physician or doctor. The published article is not a medical advice by the OWNER of the "Diabetes News Chronicle" website or by the AUTHOR of the article.


Published by Jammi Vasista, Chennai, India.
Email Jammi[no-space]Vasista1991[at]gmail[dot]com
Phone 91-944-578-3182.
Address Diabetes News Chronicle, No 40, Kaveri Street, Rajaji Nagar, Villivakkam, Chennai, India. Pin : 600049.